Billionaire Mario Gabelli is Dumping These 5 Stocks in 2022

3. Moderna, Inc. (NASDAQ:MRNA)

Number Of Hedge Fund Holders: 41

Moderna, Inc. (NASDAQ:MRNA) is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on transformational therapeutics based on messenger RNA and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases.

On May 31, Moderna, Inc. (NASDAQ:MRNA) and The Takeda Pharmaceutical Company announced plans to transfer the marketing authorization in Japan for Moderna’s COVID-19 vaccine Spikevax. As of August 1, Moderna, Inc. (NASDAQ:MRNA) will assume responsibility for all Spikevax activities, including import, local regulatory, development, quality assurance and commercialization, while The Takeda Pharmaceutical Company will continue to provide distribution support under the current national vaccination campaign for Moderna, Inc. (NASDAQ:MRNA)’s COVID-19 vaccines for a transitional period.

Earlier this May, Piper Sandler analyst Edward Tenthoff lowered his price target on Moderna, Inc. (NASDAQ:MRNA) to $214 from $348 based on “pipeline adjustments reflecting current market conditions” but maintained an Overweight rating on the shares. The analyst adjusted his model to value Spikevax at $41.3 billion on decreased expected 2022 peak revenues of $20.65 billion.

The number of hedge funds tracked by Insider Monkey owning stakes in Moderna, Inc. (NASDAQ:MRNA) stood at 41 in Q1 2022, declining from 43 in the previous quarter. The total value of these holdings is more than $3.80 billion, down from $3.89 billion in Q4 2021. Philippe Laffont’s Coatue Management is the biggest stakeholder of Moderna, Inc. (NASDAQ:MRNA) in Q1 2022, with 6.93 million shares worth approximately $1.19 billion.

Carillon Tower Advisers mentioned Moderna, Inc. (NASDAQ:MRNA) in its Q3 2021 investor letter. Here is what the fund said:

“Moderna is a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. The stock proved to be an impressive contributor once again in the quarter, as investors continue to evaluate the potential for future growth driven primarily by the firm’s revolutionary COVID-19 vaccine. Strong global demand for the vaccine may persist for the foreseeable future in order to maintain immunity as well as provide protection against any additional future variants. The potential for the firm’s mRNA technology to be used in a number of other use cases, specifically influenza, could also provide an additional tailwind for future growth.”